Zacks: Analysts Expect Ionis Pharmaceuticals Inc (IONS) Will Announce Earnings of -$0.08 Per Share

Wall Street analysts expect Ionis Pharmaceuticals Inc (NASDAQ:IONS) to post earnings of ($0.08) per share for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Ionis Pharmaceuticals’ earnings. The highest EPS estimate is $0.29 and the lowest is ($0.50). Ionis Pharmaceuticals posted earnings per share of $0.21 during the same quarter last year, which would indicate a negative year over year growth rate of 138.1%. The business is expected to issue its next quarterly earnings results on Tuesday, February 27th.

On average, analysts expect that Ionis Pharmaceuticals will report full-year earnings of ($0.14) per share for the current financial year, with EPS estimates ranging from ($0.57) to $0.22. For the next fiscal year, analysts expect that the business will post earnings of $0.35 per share, with EPS estimates ranging from ($1.10) to $2.91. Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that follow Ionis Pharmaceuticals.

IONS has been the subject of several research analyst reports. Needham & Company LLC reissued a “buy” rating and issued a $64.00 price objective on shares of Ionis Pharmaceuticals in a report on Tuesday, October 17th. BidaskClub raised Ionis Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, December 7th. Morgan Stanley boosted their price objective on Ionis Pharmaceuticals from $45.00 to $49.00 and gave the company an “equal weight” rating in a report on Wednesday, November 8th. Zacks Investment Research lowered Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, October 26th. Finally, Stifel Nicolaus reissued a “hold” rating and issued a $50.00 price objective on shares of Ionis Pharmaceuticals in a report on Friday, October 13th. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating and six have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $50.76.

Shares of Ionis Pharmaceuticals (IONS) opened at $48.61 on Tuesday. The company has a debt-to-equity ratio of 1.50, a quick ratio of 6.21 and a current ratio of 6.25. The stock has a market capitalization of $6,040.00, a PE ratio of 347.21 and a beta of 2.53. Ionis Pharmaceuticals has a 52-week low of $37.26 and a 52-week high of $65.51.

In other news, Director Joseph Klein III sold 3,000 shares of the company’s stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $55.39, for a total transaction of $166,170.00. Following the completion of the transaction, the director now directly owns 7,127 shares of the company’s stock, valued at $394,764.53. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Elizabeth L. Hougen sold 4,000 shares of the company’s stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $57.00, for a total value of $228,000.00. Following the transaction, the senior vice president now directly owns 14,392 shares of the company’s stock, valued at $820,344. The disclosure for this sale can be found here. Insiders have sold 133,885 shares of company stock valued at $7,002,841 over the last ninety days. Corporate insiders own 2.13% of the company’s stock.

Several large investors have recently bought and sold shares of the company. Majedie Asset Management Ltd boosted its position in shares of Ionis Pharmaceuticals by 8.8% during the fourth quarter. Majedie Asset Management Ltd now owns 80,696 shares of the company’s stock worth $4,059,000 after buying an additional 6,500 shares during the period. American Century Companies Inc. boosted its position in shares of Ionis Pharmaceuticals by 3.2% during the fourth quarter. American Century Companies Inc. now owns 1,181,109 shares of the company’s stock worth $59,410,000 after buying an additional 36,583 shares during the period. North Star Asset Management Inc. acquired a new position in shares of Ionis Pharmaceuticals during the fourth quarter worth approximately $765,000. IFG Advisory LLC acquired a new position in shares of Ionis Pharmaceuticals during the fourth quarter worth approximately $256,000. Finally, Steward Partners Investment Advisory LLC boosted its position in shares of Ionis Pharmaceuticals by 163.2% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 5,198 shares of the company’s stock worth $261,000 after buying an additional 3,223 shares during the period. 91.44% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “Zacks: Analysts Expect Ionis Pharmaceuticals Inc (IONS) Will Announce Earnings of -$0.08 Per Share” was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another website, it was illegally stolen and republished in violation of U.S. and international copyright law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2018/02/06/zacks-analysts-expect-ionis-pharmaceuticals-inc-ions-will-announce-earnings-of-0-08-per-share.html.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Get a free copy of the Zacks research report on Ionis Pharmaceuticals (IONS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply